Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder

Psychiatry Investigation

Volumn 7, Issue 3, 2010, Pages 228-230

  Park, Young Min ^a   Lee, Bun Hee ^b   Lee, Heon Jeong ^c   Kang, Seung Gul ^d  

^a Inje University College of Medicine   (South Korea)

^b KARF Hospital   (South Korea)

^c College of Medicine   (South Korea)

^d Saessac Hospital   (South Korea)

Author keywords

Duloxetine; Hepatic dysfunction; Hepatotoxicity; Liver injury; Major depressive disorder

Indexed keywords

BILIRUBIN; DULOXETINE; MIRTAZAPINE;

ADULT; ANAMNESIS; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; JAUNDICE; LABORATORY TEST; LIVER DYSFUNCTION; LIVER INJURY; MAJOR DEPRESSION; MALE; OBSTRUCTIVE JAUNDICE;

EID: 77957727317     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2010.7.3.228     Document Type: Article

References (13)

1. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressivedisorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-341.
2. CYMBALTA (duloxetine hydrochloride) delayed-release capsules. Product labeling. Indianapolis, IN: Eli Lilly and Company; 2005.
3. Wernicke J, Acharya N, Strombom I, Gahimer JL, D'Souza DN, DiPietro N, et al. Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events. Curr Drug Saf 2008;3:143-153.
4. Björnsson E. Drug-induced liver injury: Hy's ride revisited. Clin Pharmacol Ther 2006;79:521-528.
5. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954. (Pubitemid 35440240)
6. Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug-induced liver injury: review article. Dig Dis Sci 2007;52:2463-2471.
7. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006; 8:E48-E54.
8. McIntyre RS, Panjwani ZD, Nguyen HT, Woldeyohannes HO, Alsuwaidan M, Soczynska JK, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4:281-285.
9. Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, et al. Answers to the most common questions about the hepatic safety profile of duloxetine. Postgrad Med 2008;120:111-118.
10. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006;7:373-385.
11. Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 2008;3:132-142.
12. Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol 2006;4:912-917. (Pubitemid 43994541)
13. Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003;2:249-262.